Benign Prostatic Hyperplasia Surgical Treatment Market Size USD 3,412.57 Million by 2034 | CAGR of 5.3%

The global Benign Prostatic Hyperplasia Surgical Treatment Market size was valued at USD 2,042.94 million in 2024 and is expected to grow at a CAGR of 5.3%

NEW YORK CITY, DE, UNITED STATES, September 10, 2025 /EINPresswire.com/ -- The [global benign prostatic hyperplasia (BPH) surgical treatment market size] was valued at USD 2,042.94 million in 2024 and is projected to reach USD 3,412.57 million by 2034, according to a recent report by Polaris Market Research.

> The aging male population's growing need for BPH treatment, improvements in minimally invasive urology, and growing knowledge of treatments with better results all contribute to the market's expansion”
>
> *Polaris Market Research*

The BPH surgical treatment market is expected to register a significant CAGR of 5.3% from 2025 to 2034. Growing demand for BPH treatment among aging men, innovations in minimally invasive urology, and greater awareness of effective treatment options are driving market growth.

□□□ □□□□□□□□□□ □□□□ □□□ □□□□□□

- North America led the market, generating the highest revenue of USD 888.88 million in 2024.
- Asia Pacific held a 21.61% share of the global market in 2024.
- Europe is expected to reach USD 963.03 million.
- Based on type analysis, the transurethral resection of the prostate (TURP) segment led the market with a value of USD 713.43 million in 2024.
- According to end user insights, hospitals held the largest revenue share in 2024, valued at USD 1,304.27 million.

□□□□□□ □□□□□□□□

Benign prostatic hyperplasia (BPH) surgical treatment is a medical procedure designed to relieve symptoms caused by the enlargement of the prostate gland. These surgeries aim to reduce prostate size or remove excess tissue to improve urine flow and alleviate urinary problems commonly associated with BPH.

□□□□□□□□ □□□□□□□□□. □□□□□□□ □□□□ □□□□□ □□□□□□□: https://www.polarismarketresearch.com/industry-analysis/benign-prostatic-hyperplasia-surgical-treatment-market/request-for-sample



Benign Prostatic Hyperplasia Surgical Treatment Market

□□□□□□ □□□□□□□ □□ □□□□□□□□ □□□□ □□□□□□□?

□□□□□□□ □□□□□□ □□ □□□□ □□□□□□□□

Region Share:

North America- USD 888.88 million in 2024

U.S. - USD 714.48 million in 2024

Asia Pacific - 21.61% share in 2024

China - 6.4% during the forecast period

Europe - USD 963.03 million during the forecast period

□ North America led the benign prostatic hyperplasia surgical treatment market in 2024, valued at USD 888.88 million, driven by high BPH prevalence, advanced surgical techniques, and strong healthcare spending. The region’s robust healthcare infrastructure and ongoing innovation support early diagnosis and widespread adoption of advanced treatments.
□ The U.S. market leads regionally, driven by advanced healthcare infrastructure, high awareness, widespread access to specialized procedures, and strong support from insurance and clinical guidelines.
□ Asia Pacific held a 21.61% share of the global market in 2024, driven by rising urological health awareness and increased healthcare investments. Rapid urbanization, a growing elderly population, and improved access to modern surgical care are fueling demand, positioning the region as a key growth area for BPH treatments.
□ Increased healthcare investments, rising prostate health awareness, a growing elderly population, and strong government support for healthcare modernization fuel the market growth in China.
□ Europe is projected to reach USD 963.03 million, driven by medical innovations, supportive policies, and efficient reimbursement systems. A strong focus on minimally invasive care and structured clinical guidelines continues to boost adoption across the region.

- The UK market growth is supported by a rising preference for minimally invasive procedures, improved healthcare delivery, effective referral systems, and a strong emphasis on early diagnosis and timely intervention.

[illegible]

The BPH surgical treatment market is advancing through tech innovation, rising demand, and growth in emerging regions. North America leads with high adoption of advanced procedures, while Asia Pacific shows strong potential due to increasing healthcare investment. Ambulatory surgery centers are gaining traction as cost-effective outpatient options, and key players are focusing on partnerships, precision, and affordability to stay competitive.

[illegible]

- Alembic Pharmaceuticals Limited
- Asahi Kasei Corporation
- Boston Scientific Corporation
- Cleveland Clinic
- Coloplast Group
- Cook Medical
- Karl Storz SE & Co. KG
- Medifocus, Inc.
- Medtronic
- Olympus Corporation
- The Johns Hopkins Hospital

[illegible]: https://www.polarismarketresearch.com/press-releases/benign-prostatic-hyperplasia-surgical-treatment-market

[illegible]

[illegible]?

[illegible]

The growing elderly male population is driving demand in the market, as age-related prostate enlargement becomes more common. With the global population aged 60+ projected to reach 1.4 billion by 2030 (WHO, 2025), more patients are seeking effective, long-term solutions. This trend is increasing the need for timely surgical interventions that improve both urinary function and overall quality of life.

[illegible]

Advanced technologies such as laser procedures, [surgery robots](), and real-time imaging are accelerating the evolution of BPH treatment. These advancements improve precision, reduce recovery time, and enhance outcomes, making surgical options more appealing and expanding the market for minimally invasive care.

[illegible]: [illegible]

The BPH surgical treatment market faces challenges due to the high cost of advanced procedures like laser and robotic surgeries, which limit access in lower-income regions. Additionally, the availability of non-surgical alternatives and concerns over potential complications can reduce patient willingness to opt for surgical intervention, slowing market expansion.

[illegible]: [illegible]

The shift toward minimally invasive procedures offers strong growth potential for the BPH surgical treatment market. Rising patient preference, expanding healthcare access in emerging regions, and ongoing technological innovation are key drivers creating new market opportunities.

[illegible]. [illegible]:
https://www.polarismarketresearch.com/industry-analysis/benign-prostatic-hyperplasia-surgical-treatment-market

[illegible]

[illegible]

- Transurethral Resection of the Prostate (TURP) Segment: USD 713.43 million in 2024
- Hospitals Segment: USD 1,304.27 million in 2024
- Ambulatory Surgery Centers (ASCs) Segment: 5.7% during the forecast period

By Type

The BPH surgical treatment market is divided into several types. In 2024, transurethral resection of the prostate (TURP) is expected to dominate with USD 713.43 million. Its proven effectiveness, safety, and widespread use make TURP the preferred standard of care in healthcare facilities around the world.

The prostatic urethral lift segment is also set for strong growth, driven by its minimally invasive approach, quicker recovery, and preservation of sexual function. Increasing awareness of effective alternatives to traditional procedures is further boosting its adoption.

By End User

Hospitals remain the preferred end users due to their advanced diagnostic capabilities, specialized expertise, and comprehensive surgical infrastructure, making them central to managing both routine and complex urological procedures.

The ambulatory surgery centers (ASCs) segment is also expected to grow fastest, with a CAGR of 5.7%, driven by the rising demand for cost-effective, outpatient BPH procedures. Advances in technology and greater accessibility are making ASCs a preferred choice for minimally invasive surgeries, boosting patient convenience and satisfaction.

□□□□ □□□ □□□ □□□ □□□□□□□□□□□□ □□ □□□□□□□ □□□□□□□□□□ □□□□□?

April 2025: Rivermark Medical announced the initiation of the RAPID III clinical trial. It enrolled the first patients to evaluate the effectiveness of the FloStent System for treating benign prostatic hyperplasia (BPH). According to Rivermark Medical, the prospective and randomized pivotal trial aims to provide a non-surgical and reversible treatment for BPH patients.

February 2025: Olympus APAC announced expanded availability of its iTind device for BPH treatment across the Asia Pacific. The minimally invasive device provides an outpatient solution for lower urinary tract symptoms caused by BPH. The expanded availability in APAC strengthens access to innovative urological care in the region.

□□□□□□ □□□□□□□□□□□□

By Type Outlook

- Transurethral Resection of the Prostate (TURP)
- Prostatic Urethral Lift
- Water Vapor Therapy
- Laser Therapy
- Aquablation Therapy
- Transurethral Microwave Thermotherapy (TUMT)
- Others

By End User Outlook

- Hospitals
- Ambulatory Surgery Centers and Clinics
- Homecare Settings

By Regional Outlook

- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Netherlands
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Malaysia
- South Korea
- Indonesia
- Australia
- Vietnam
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Mexico
- Brazil
- Argentina
- Rest of Latin America

Thank you for reading. You can also request customized sections of this report, including chapter-wise breakdowns or region-specific versions such as North America, Europe, Asia Pacific, and more. https://www.polarismarketresearch.com/industry-analysis/benign-prostatic-hyperplasia-surgical-treatment-market/request-for-customization

Immediate Delivery Available | Buy This Premium Research Report

Have questions or need help placing an order?

Feel free to contact us at:
Stay Ahead with Polaris Market Research

Gain exclusive access to in-depth market intelligence, real-time industry updates, and expert-driven insights tailored to your strategic goals. Whether you're tracking trends or evaluating competitors, our subscription plans empower your decision-making with up-to-date, actionable data.

□□□□□ □□□□□□□□ □□□□□□□ □□□□□□□□□

Polaris Market Research is a leading provider of market research and intelligence solutions. The company specializes in providing comprehensive market research reports to clients across various sectors. Polaris is committed to serving its diverse client base, which spans industries such as technology, healthcare, chemicals, and semiconductors, amongst others. Our reports have up-to-date information on emerging technologies, recent developments, and high-growth markets. By going through our reports, businesses can make informed decisions and capitalize on new opportunities. Our team of expert analysts and consultants is there to help you with your queries and research needs.

□□□□□□□□ □□:
Polaris Market Research & Consulting, Inc.
8 The Green Ste 19824,
Dover, DE 19901, United States
Email: sales@polarismarketresearch.com
Website: https://www.polarismarketresearch.com
Phone: +1 929-297-9727

Sheetal Chatur
Polaris Market Research and Consulting
+1 929-297-9727
email us here
Visit us on social media:
LinkedIn
Facebook
X